Key result
Anti-ischaemic drug therapy added to risk factor control significantly reduced the composite of cardiac death, MI, or ACS compared to risk factor control alone (12% vs 61%, P<0.001).
Why the study?
Does anti-ischaemic drug therapy reduce cardiac events in asymptomatic patients with silent myocardial ischaemia type I?
Population
54 asymptomatic subjects without coronary artery disease history but at least one CAD risk factor, with…
Comparison
Anti-anginal drug therapy and aspirin in… vs Risk factor control-only
Design
RCT, randomized
Follow-up
11.2 +/- 2.2 years
Authors
Loading...
Anti-ischaemic addition may reduce events; pilot data leave open confirmation in randomized trials before practice change.
RCT (n=54)
Yes
Does anti-ischaemic drug therapy reduce cardiac events in asymptomatic patients with silent myocardial ischaemia type I?
Absolute Event Rate: 12% vs 61%
p-value: p=< 0.001
Anti-ischaemic drug therapy significantly reduces long-term cardiac events and preserves left ventricular ejection fraction in asymptomatic patients with silent myocardial ischaemia type I.
Erné et al. (2007) conducted an RCT in Silent myocardial ischaemia type I (n=54). Anti-ischaemic drug therapy vs. Risk factor control only was evaluated on Cardiac death, non-fatal myocardial infarction, or acute coronary syndrome requiring hospitalization or revascularization (p=< 0.001). Anti-ischaemic drug therapy added to risk factor control significantly reduced the composite of cardiac death, MI, or ACS compared to risk factor control alone (12% vs 61%, P<0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: